HXN5003
/ Helixon Biotechnology (Suzhou)
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 04, 2026
A Phase I Study of HXN5003 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
(clinicaltrials.gov)
- P1 | N=68 | Not yet recruiting | Sponsor: Helixon Biotechnology (Suzhou) Co., Ltd
New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
1 to 1
Of
1
Go to page
1